Skip to main content
Top
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Research article

Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis

Authors: Cibele Grothe, Mônica Taminato, Angélica Belasco, Ricardo Sesso, Dulce Barbosa

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

This study was performed to evaluate the clinical effectiveness of alternative strategies for the prevention and treatment of patients with chronic kidney disease undergoing peritoneal dialysis and colonized by Staphylococcus aureus.

Methods

A systematic review and meta-analysis were performed. The literature search involved the following databases: the Cochrane Controlled Trials Register, Embase, LILACS, CINAHL, SciELO, and PubMed/Medline. The descriptors were “Staphylococcus aureus,” “MRSA,” “MSSA,” “treatment,” “decolonization,” “nasal carrier,” “colonization,” “chronic kidney disease,” “dialysis,” and “peritoneal dialysis.” Randomized controlled trials that exhibited agreement among reviewers as shown by a kappa value of >0.80 were included in the study; methodological quality was evaluated using the STROBE statement. Patients who received various antibiotic treatments (antibiotic group) or topical mupirocin (mupirocin group) were compared with those who received either no treatment or placebo (control group). Patients in the antibiotic group were also compared with those in the mupirocin group.

Results

In total, nine studies involving 839 patients were included in the analysis, 187 (22.3 %) of whom were nasal carriers of S. aureus. The probability of S. aureus infection at the catheter site for peritoneal dialysis was 74 % lower in the mupirocin than control group (odds ratio [OR], 0.26; 95 % confidence interval [CI], 0.14–0.46; p < 0.001), 56 % lower in the antibiotic than control group (OR, 0.44; 95 % CI, 0.19–0.99; p = 0.048), and 52 % lower in the mupirocin than antibiotic group (OR, 0.48; 95 % CI, 0.21–1.10; p = 0.084). The difference in the probability of S. aureus peritonitis in patients undergoing peritoneal dialysis was not statistically significant among the three groups.

Conclusions

Mupirocin and topical antibiotics were effective for reduction of S. aureus catheter site infection in patients undergoing peritoneal dialysis when compared with no treatment or placebo. However, evidence was insufficient to identify the optimal agent, route, or duration of antibiotics to treat peritonitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pignatari A, Pfaller M, Hollis R, Sesso R, Leme I, Herwaldt L. Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol. 1990;28(9):1898–902.PubMedPubMedCentral Pignatari A, Pfaller M, Hollis R, Sesso R, Leme I, Herwaldt L. Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol. 1990;28(9):1898–902.PubMedPubMedCentral
2.
go back to reference Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, ISPD Ad Hoc Advisory Committee, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005;25:107–31.PubMed Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, ISPD Ad Hoc Advisory Committee, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005;25:107–31.PubMed
3.
go back to reference Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int. 2011;31:614–30.CrossRefPubMed Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int. 2011;31:614–30.CrossRefPubMed
4.
go back to reference Figueiredo AE, Figueiredo CEP, Meneghetti F, Lise GAP, Detofoli CC, Silva LB. Peritonites em pacientes em diálise peritoneal: análise de um único centro brasileiro segundo a Sociedade Internacional de Diálise Peritoneal. J Bras Nefrol. 2013;35(3):214. Figueiredo AE, Figueiredo CEP, Meneghetti F, Lise GAP, Detofoli CC, Silva LB. Peritonites em pacientes em diálise peritoneal: análise de um único centro brasileiro segundo a Sociedade Internacional de Diálise Peritoneal. J Bras Nefrol. 2013;35(3):214.
5.
go back to reference Cleper R, Davidovits M, Kovalski Y, Samsonov D, Amir J, Krause I. Peritonitis in a pediatric dialysis unit: local profile and implications. Isr Med Assoc J. 2010;12:348–52.PubMed Cleper R, Davidovits M, Kovalski Y, Samsonov D, Amir J, Krause I. Peritonitis in a pediatric dialysis unit: local profile and implications. Isr Med Assoc J. 2010;12:348–52.PubMed
6.
go back to reference Barretti P, Bastos KA, Dominguez J, Caramori JC. Peritonitis in Latin America. Perit Dial Int. 2007;27:332–9.PubMed Barretti P, Bastos KA, Dominguez J, Caramori JC. Peritonitis in Latin America. Perit Dial Int. 2007;27:332–9.PubMed
7.
go back to reference Grothe C, Belasco AG, Bittencourt AR, Vianna LA, Sesso R, Barbosa DA. Incidence of bloodstream infection among patients on hemodialysis by central venous catheter. Rev Lat Am Enfermagem. 2010;18(1):73–80.CrossRefPubMed Grothe C, Belasco AG, Bittencourt AR, Vianna LA, Sesso R, Barbosa DA. Incidence of bloodstream infection among patients on hemodialysis by central venous catheter. Rev Lat Am Enfermagem. 2010;18(1):73–80.CrossRefPubMed
8.
go back to reference Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of 404 Staphylococcus aureus bacteremia. Study Group. 2001;344(1):11–6. Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of 404 Staphylococcus aureus bacteremia. Study Group. 2001;344(1):11–6.
9.
go back to reference Aktaş E, Pazarli O, Külah C, Cömert F, Külah E, Sümbüloğlu V. Determination of Staphylococcus aureus carriage in hemodialysis and peritoneal dialysis patients and evaluation of the clonal relationship between carriage and clinical isolates. Am J Infect Control. 2011;39:421–5.CrossRefPubMed Aktaş E, Pazarli O, Külah C, Cömert F, Külah E, Sümbüloğlu V. Determination of Staphylococcus aureus carriage in hemodialysis and peritoneal dialysis patients and evaluation of the clonal relationship between carriage and clinical isolates. Am J Infect Control. 2011;39:421–5.CrossRefPubMed
10.
go back to reference Barbosa DA, Dalboni M, Leme I, Rabello T, Pignatari AC, Sesso R. Staphylococcus aureus nasal carrier state in CAPD patients - a four years study. In: Mollby R, Flock JI, Nord CE, Christensson B, editors. Staphylococci and Staphylococcal infection. New York: Gustav Fischer Verlag; 1994. p. 159–61. Barbosa DA, Dalboni M, Leme I, Rabello T, Pignatari AC, Sesso R. Staphylococcus aureus nasal carrier state in CAPD patients - a four years study. In: Mollby R, Flock JI, Nord CE, Christensson B, editors. Staphylococci and Staphylococcal infection. New York: Gustav Fischer Verlag; 1994. p. 159–61.
11.
go back to reference Moore C, Dhaliwal J, Tong A, Eden S, Wigston C, Willey B, McGeer A. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) acquisition in roommate contacts of patients colonized or infected with MRSA in an acute-care hospital. Infect Control Hosp Epidemiol. 2008;29:600–6.CrossRefPubMed Moore C, Dhaliwal J, Tong A, Eden S, Wigston C, Willey B, McGeer A. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) acquisition in roommate contacts of patients colonized or infected with MRSA in an acute-care hospital. Infect Control Hosp Epidemiol. 2008;29:600–6.CrossRefPubMed
12.
go back to reference Zimmerman SW, Johnson CA. Rifampin use in peritoneal dialysis. Perit Dial Int. 1989;9(4):241-3. Zimmerman SW, Johnson CA. Rifampin use in peritoneal dialysis. Perit Dial Int. 1989;9(4):241-3.
13.
go back to reference Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of intervention. Chichester (UK): John Wiley & Sons; 2005. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of intervention. Chichester (UK): John Wiley & Sons; 2005.
14.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting itms for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting itms for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.CrossRefPubMed
15.
go back to reference Rev Man Analyses (RevMan) [computer software] Version 1.0 for Windows, in Review Manager 5.1. Oxford: The Cochrane Collaboration; 2005. Rev Man Analyses (RevMan) [computer software] Version 1.0 for Windows, in Review Manager 5.1. Oxford: The Cochrane Collaboration; 2005.
16.
go back to reference The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peri- toneal dialysis. J Am Soc Nephrol. 1996;7:2403–8. The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peri- toneal dialysis. J Am Soc Nephrol. 1996;7:2403–8.
17.
go back to reference Wong SSH, Chu K-H, Cheuk A, Tsang WK, Fung SKS, Chan HWH, et al. Prophylaxis against Gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. Perit Dial Int. 2003;23 Suppl 2:S153–8.PubMed Wong SSH, Chu K-H, Cheuk A, Tsang WK, Fung SKS, Chan HWH, et al. Prophylaxis against Gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. Perit Dial Int. 2003;23 Suppl 2:S153–8.PubMed
18.
go back to reference Zimmerman S, Ahrens E, Johnson C, Craig W, Leggett J, O’Brien M, et al.Randomized controlled trial of pro- phylactic rifampin for peritoneal dialysis-related in- fections. Am J Kidney Dis. 1991;18(2):225-31. Zimmerman S, Ahrens E, Johnson C, Craig W, Leggett J, O’Brien M, et al.Randomized controlled trial of pro- phylactic rifampin for peritoneal dialysis-related in- fections. Am J Kidney Dis. 1991;18(2):225-31.
19.
go back to reference Lye WC, Leong SO, van der Straaten J, Lee EJ. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv Perit Dial. 1994;10:163–5.PubMed Lye WC, Leong SO, van der Straaten J, Lee EJ. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv Perit Dial. 1994;10:163–5.PubMed
20.
go back to reference Sesso R, Barbosa D, Leme I, Sader H, Canziani ME, Manfredi S, et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol. 1998;9(6):1085–92.PubMed Sesso R, Barbosa D, Leme I, Sader H, Canziani ME, Manfredi S, et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol. 1998;9(6):1085–92.PubMed
21.
go back to reference Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol. 2005;16:539–45.CrossRefPubMed Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol. 2005;16:539–45.CrossRefPubMed
22.
go back to reference Perez-Fontan M, Garcia-Falcon T, Rosales M, et al. Treatment of Staph- ylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kid Dis. 1993;22:708–12.CrossRefPubMed Perez-Fontan M, Garcia-Falcon T, Rosales M, et al. Treatment of Staph- ylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kid Dis. 1993;22:708–12.CrossRefPubMed
23.
go back to reference Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2 % applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996;27:695–700.CrossRefPubMed Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2 % applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996;27:695–700.CrossRefPubMed
24.
go back to reference Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis – first 6 months’ experience. Adv Perit Dial. 2004;20:62–6.PubMed Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis – first 6 months’ experience. Adv Perit Dial. 2004;20:62–6.PubMed
25.
go back to reference Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H, Mallaghan, Tucker DR. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63 Suppl 1:S1-44. Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H, Mallaghan, Tucker DR. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63 Suppl 1:S1-44.
27.
go back to reference National Institute for Health and Clinical Excellence. Surgical site infection: prevention and treatment of surgical site infection. London (UK): NIHCE; 2008. National Institute for Health and Clinical Excellence. Surgical site infection: prevention and treatment of surgical site infection. London (UK): NIHCE; 2008.
28.
go back to reference Krediet RT. European best practice guidelines on peritoneal dialysis. Nephrol Dial Transplant. 2005;20(Suppl 9):ix8-ix12. Krediet RT. European best practice guidelines on peritoneal dialysis. Nephrol Dial Transplant. 2005;20(Suppl 9):ix8-ix12.
Metadata
Title
Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis
Authors
Cibele Grothe
Mônica Taminato
Angélica Belasco
Ricardo Sesso
Dulce Barbosa
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0329-0

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.